Secondary analysis of the phase 3 EMBARK trial in high-risk biochemically recurrent prostate cancer: enzalutamide plus leuprolide vs leuprolide alone had higher 5-year freedom from distant metastasis (91.0% vs 81.5%) and castration resistance (96.6% vs 67.8%).
Secondary analysis
Shore et al. Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial